Thompson Davis & Co’s AstraZeneca AZN Stock Holding History

Thompson Davis & Co’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-750	Closed	-$45K	–	1098
2016 Q2	$45K	Buy	+750	New	+$43.6K	0.07%	261
2015 Q4	–	Sell	-145	Closed	-$9K	–	1129
2015 Q3	$9K	Hold	145	–	–	0.01%	676
2015 Q2	$9K	Hold	145	–	–	0.01%	729
2015 Q1	$10K	Hold	145	–	–	0.01%	724
2014 Q4	$10K	Hold	145	–	–	0.01%	732
2014 Q3	$10K	Hold	145	–	–	0.01%	692
2014 Q2	$11K	Hold	145	–	–	0.02%	472
2014 Q1	$9K	Hold	145	–	–	0.01%	501
2013 Q4	$9K	Buy	+145	New	+$7.88K	0.01%	462

Other funds holding AZN

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

BIM

BlackRock Investment Management Wilmington, Delaware $86.4B AUM 16.83% 1-Year Est. Return

EIP

Epoch Investment Partners New York $17.6B AUM 34.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Thompson Davis & Co's AZN Position: Q3 2016 in Review

Thompson Davis & Co sold out of AstraZeneca (AZN) in Q3 2016, closing a stake of 750 shares — an estimated $45K sold.

Thompson Davis & Co first reported a position in AZN in Q4 2013 and held it in 9 quarters. The position peaked at $45K in Q2 2016. 451 funds tracked by Wall St. Rank hold AZN as of Q3 2016.

Thompson Davis & Co reported no remaining AstraZeneca position as of Q3 2016 after selling out during the quarter.
Thompson Davis & Co sold 750 AstraZeneca shares in Q3 2016, an estimated $45K.
Thompson Davis & Co first reported a position in AstraZeneca in Q4 2013 and held it in 9 quarters.
Thompson Davis & Co's AstraZeneca position peaked at $45K in Q2 2016.
451 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2016.

Based on Thompson Davis & Co's 13F filing for Q3 2016, filed 8 Nov 2016.